HMGB1 serum levels as a potential new biomarker of disease severity in recessive dystrophic epidermolysis bullosa

被引：0
|
作者：
Petrof, G. [1 ]
McGrath, J. [1 ]
机构：
[1] Kings Coll London, St Johns Inst Dermatol, London WC2R 2LS, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2012年 / 166卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：e38 / e38
页数：1
相关论文
共 50 条
  • [41] Does the position of the premature termination codon in COL7A1 correlate with the clinical severity in recessive dystrophic epidermolysis bullosa?
    Ishiko, A
    Masunaga, T
    Ota, T
    Nishikawa, T
    EXPERIMENTAL DERMATOLOGY, 2004, 13 (04) : 229 - 233
  • [42] Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases
    Ying, Shibo
    Jiang, Zhaoqiang
    He, Xianglei
    Yu, Min
    Chen, Riping
    Chen, Junqiang
    Ru, Guoqing
    Chen, Yuan
    Chen, Wanyuan
    Zhu, Lijin
    Li, Tao
    Zhang, Yixiao
    Guo, Xinnian
    Yin, Xianhong
    Zhang, Xing
    Lou, Jianlin
    DISEASE MARKERS, 2017, 2017
  • [43] Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
    Nystroem, Alexander
    Thriene, Kerstin
    Mittapalli, Venugopal
    Kern, Johannes S.
    Kiritsi, Dimitra
    Dengjel, Joern
    Bruckner-Tuderman, Leena
    EMBO MOLECULAR MEDICINE, 2015, 7 (09) : 1211 - 1228
  • [44] Diagnostic dilemma of "sporadic" cases of dystrophic epidermolysis bullosa: a new dominant or mitis recessive mutation?
    Hashimoto, I
    Kon, A
    Tamai, K
    Uitto, J
    EXPERIMENTAL DERMATOLOGY, 1999, 8 (02) : 140 - 142
  • [45] Gene therapy and bilayered skin substitutes as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa skin wounds
    Barbier, Martin A.
    Piaceski, Angela Dakiw
    Savard, Etienne
    Morissette, Amelie
    Larose, Alex
    Larouche, Danielle
    Ghani, Karim
    Pope, Elena
    Caruso, Manuel
    Germain, Lucie
    WOUND REPAIR AND REGENERATION, 2022, 30 (05) : A10 - A10
  • [46] Potential consequences of the interaction of squamous cell carcinoma cells with EDA fibronectin in recessive dystrophic epidermolysis bullosa
    Rosenbloom, J.
    Montgomery, M.
    South, A. P.
    Uitto, J.
    Macarak, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S24 - S24
  • [47] Novel biallelic variants in COL7A1 cause recessive dystrophic epidermolysis bullosa
    Yang, Neng
    Ma, Yongyi
    Yao, Hong
    Chang, Qing
    Zhang, Victor
    Liang, Zhiqing
    Cai, Xiongwei
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2020, 8 (08):
  • [48] Systemic isotretinoin and recessive dystrophic epidermolysis bullosa (RDEB): Results of a phase 1 clinical trial
    Weiner, M
    Fine, J
    Stein, A
    Suchindran, C
    Johnson, L
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 543 - 543
  • [49] Recessive dystrophic epidermolysis bullosa caused by a novel COL7A1 variant with isodisomy
    Niida, Yo
    Kobayashi, Azusa
    Togi, Sumihito
    Ura, Hiroki
    HUMAN GENOME VARIATION, 2023, 10 (01)
  • [50] In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial
    Irina Gurevich
    Pooja Agarwal
    PeiPei Zhang
    John A. Dolorito
    Stacie Oliver
    Henry Liu
    Nicholas Reitze
    Nikhil Sarma
    Isin Sinem Bagci
    Kunju Sridhar
    Visesha Kakarla
    Vamsi K. Yenamandra
    Mark O’Malley
    Marco Prisco
    Sara F. Tufa
    Douglas R. Keene
    Andrew P. South
    Suma M. Krishnan
    M. Peter Marinkovich
    Nature Medicine, 2022, 28 : 780 - 788
12345